OBJECTIVE: In vivo imaging studies have revealed deregulated presynaptic or postsynaptic function of the midbrain dopaminergic system in patients with schizophrenia. To further delineate the neuropathological involvement of the presynaptic and postsynaptic dopamine neurons in schizophrenia, the authors examined brain D(2)-family receptor and dopamine transporter binding simultaneously in patients with drug-naive schizophrenia using the dual-isotope single photon emission computed tomography (SPECT) imaging technique. METHOD: Eleven patients with schizophrenia and 12 healthy comparison subjects were recruited. Striatal dopamine D(2)/D(3) receptor was measured with SPECT and [(123)I]iodobenzamide ([(123)I]IBZM), while dopamine transporter was measured with SPECT and [(99m)Tc]TRODAT-1. RESULTS: Striatal D(2)/D(3) receptor and dopamine transporter binding were unaltered in these drug-naive patients with schizophrenia. Nonetheless, D(2)/D(3) receptor binding measures were positively correlated with dopamine transporter binding measures in these patients but not in the comparison subjects. CONCLUSIONS: The associated presynaptic and postsynaptic disturbances of midbrain dopamine neurons could be clinically relevant in drug-naive patients with schizophrenia.
OBJECTIVE: In vivo imaging studies have revealed deregulated presynaptic or postsynaptic function of the midbrain dopaminergic system in patients with schizophrenia. To further delineate the neuropathological involvement of the presynaptic and postsynaptic dopamine neurons in schizophrenia, the authors examined brain D(2)-family receptor and dopamine transporter binding simultaneously in patients with drug-naive schizophrenia using the dual-isotope single photon emission computed tomography (SPECT) imaging technique. METHOD: Eleven patients with schizophrenia and 12 healthy comparison subjects were recruited. Striatal dopamine D(2)/D(3) receptor was measured with SPECT and [(123)I]iodobenzamide ([(123)I]IBZM), while dopamine transporter was measured with SPECT and [(99m)Tc]TRODAT-1. RESULTS: Striatal D(2)/D(3) receptor and dopamine transporter binding were unaltered in these drug-naive patients with schizophrenia. Nonetheless, D(2)/D(3) receptor binding measures were positively correlated with dopamine transporter binding measures in these patients but not in the comparison subjects. CONCLUSIONS: The associated presynaptic and postsynaptic disturbances of midbrain dopamine neurons could be clinically relevant in drug-naive patients with schizophrenia.
Authors: G J E Schmitt; T Frodl; S Dresel; C la Fougère; R Bottlender; N Koutsouleris; K Hahn; H-J Möller; E M Meisenzahl Journal: Eur Arch Psychiatry Clin Neurosci Date: 2005-11-15 Impact factor: 5.270
Authors: G J E Schmitt; S Dresel; T Frodl; C la Fougère; R Boerner; K Hahn; H-J Möller; E M Meisenzahl Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-11-13 Impact factor: 5.270
Authors: Y Hodé; M Reimold; A Demazières; G Reischl; F Bayle; P Nuss; A Hameg; M Dib; J P Macher Journal: Psychopharmacology (Berl) Date: 2005-03-15 Impact factor: 4.530
Authors: Michael E Talkowski; Kathleen L McCann; Michael Chen; Lora McClain; Mikhil Bamne; Joel Wood; Kodavali V Chowdari; Annie Watson; Konasale M Prasad; George Kirov; Lyudmilla Georgieva; Draga Toncheva; Hader Mansour; David A Lewis; Michael Owen; Michael O'Donovan; Panagiotis Papasaikas; Patrick Sullivan; Douglas Ruderfer; Jeffrey K Yao; Sherry Leonard; Pramod Thomas; Fabio Miyajima; John Quinn; A Javier Lopez; Vishwajit L Nimgaonkar Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-10-18 Impact factor: 3.568
Authors: Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham Journal: Biol Psychiatry Date: 2016-03-31 Impact factor: 13.382